JANX (Janux Therapeutics) Valuation Rank


JANX Janux Therapeutics Inc JANX
46 GF Score
Price $15.54
GF Value $39.91
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Janux Therapeutics Valuation Rank Related Terms

JANX
46GF Score
Janux Therapeutics Inc JANX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $15.54 is trading 61.1% below its estimated GF Value™ of $39.91. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • Valuation Rank:
  • GF Value™: $39.91 vs. price of $15.54 (61.1% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score

Get the complete analysis for JANX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.54
Price
$39.91
GF Value